FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514912829> ?p ?o ?g. }

• W2514912829 endingPage "212" @default.
• W2514912829 startingPage "203" @default.
• W2514912829 abstract "Objective Lesinurad is a selective uric acid reabsorption inhibitor used for the treatment of gout in combination with a xanthine oxidase inhibitor. The Combining Lesinurad with Allopurinol Standard of Care in Inadequate Responders (CLEAR 1) study, a 12‐month, multicenter, randomized, double‐blind, placebo‐controlled phase III trial, was conducted to investigate daily lesinurad (200 mg or 400 mg orally) added to allopurinol versus placebo plus allopurinol in patients with serum urate (UA) levels above a target of <6.0 mg/dl. Methods Patients receiving ≥300 mg of allopurinol (≥200 mg in those with moderate renal impairment) who had serum UA levels ≥6.5 mg/dl at screening and ≥2 gout flares during the previous year were studied. The primary end point was the proportion of patients achieving a serum UA level of <6.0 mg/dl at month 6. Key secondary end points were the mean gout flare rate requiring treatment (months 7–12) and the proportions of patients with complete resolution of ≥1 target tophus (month 12). Safety assessments included adverse events and laboratory data. Results The study patients (n = 603) were predominantly male and had a mean ± SD age of 51.9 ± 11.3 years, a gout duration of 11.8 ± 9.4 years, a baseline serum UA level of 6.94 ± 1.27 mg/dl, and were receiving an allopurinol dosage of 306.6 ± 59.58 mg/day. Lesinurad at doses of 200 mg or 400 mg added to allopurinol therapy significantly increased the proportions of patients who achieved serum UA target levels by month 6 as compared with those receiving allopurinol alone (54.2%, 59.2%, and 27.9%, respectively, P < 0.0001). Lesinurad was not significantly superior to allopurinol alone in terms of the secondary end points: rates of gout flares and complete resolution of tophi. Lesinurad was generally well‐tolerated; the safety profile of the 200‐mg dose was comparable to that of allopurinol alone, except for higher incidences of predominantly reversible elevations of serum creatinine levels. Conclusion Lesinurad added to allopurinol provided benefit as compared with allopurinol alone in reducing serum UA levels and represents a new treatment option for patients needing additional urate‐lowering therapy." @default.
• W2514912829 created "2016-09-16" @default.
• W2514912829 creator A5008586613 @default.
• W2514912829 creator A5017811122 @default.
• W2514912829 creator A5021595675 @default.
• W2514912829 creator A5032801878 @default.
• W2514912829 creator A5042159963 @default.
• W2514912829 creator A5046382845 @default.
• W2514912829 creator A5058566347 @default.
• W2514912829 creator A5060122908 @default.
• W2514912829 creator A5069157708 @default.
• W2514912829 date "2016-12-28" @default.
• W2514912829 modified "2023-10-02" @default.
• W2514912829 title "Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study)" @default.
• W2514912829 cites W170894788 @default.
• W2514912829 cites W1971469286 @default.
• W2514912829 cites W1977479621 @default.
• W2514912829 cites W1982824807 @default.
• W2514912829 cites W1998976537 @default.
• W2514912829 cites W2000166571 @default.
• W2514912829 cites W2012029752 @default.
• W2514912829 cites W2025971045 @default.
• W2514912829 cites W2044334793 @default.
• W2514912829 cites W2055515705 @default.
• W2514912829 cites W2098144815 @default.
• W2514912829 cites W2106983312 @default.
• W2514912829 cites W2107225963 @default.
• W2514912829 cites W2108262590 @default.
• W2514912829 cites W2112346753 @default.
• W2514912829 cites W2114365596 @default.
• W2514912829 cites W2116231610 @default.
• W2514912829 cites W2119515450 @default.
• W2514912829 cites W2121179535 @default.
• W2514912829 cites W2130470649 @default.
• W2514912829 cites W2134743466 @default.
• W2514912829 cites W2139937737 @default.
• W2514912829 cites W2150866339 @default.
• W2514912829 cites W2151809600 @default.
• W2514912829 cites W2156131531 @default.
• W2514912829 cites W2170246607 @default.
• W2514912829 cites W2328742493 @default.
• W2514912829 doi "https://doi.org/10.1002/art.39840" @default.
• W2514912829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27564409" @default.
• W2514912829 hasPublicationYear "2016" @default.
• W2514912829 type Work @default.
• W2514912829 sameAs 2514912829 @default.
• W2514912829 citedByCount "138" @default.
• W2514912829 countsByYear W25149128292016 @default.
• W2514912829 countsByYear W25149128292017 @default.
• W2514912829 countsByYear W25149128292018 @default.
• W2514912829 countsByYear W25149128292019 @default.
• W2514912829 countsByYear W25149128292020 @default.
• W2514912829 countsByYear W25149128292021 @default.
• W2514912829 countsByYear W25149128292022 @default.
• W2514912829 countsByYear W25149128292023 @default.
• W2514912829 crossrefType "journal-article" @default.
• W2514912829 hasAuthorship W2514912829A5008586613 @default.
• W2514912829 hasAuthorship W2514912829A5017811122 @default.
• W2514912829 hasAuthorship W2514912829A5021595675 @default.
• W2514912829 hasAuthorship W2514912829A5032801878 @default.
• W2514912829 hasAuthorship W2514912829A5042159963 @default.
• W2514912829 hasAuthorship W2514912829A5046382845 @default.
• W2514912829 hasAuthorship W2514912829A5058566347 @default.
• W2514912829 hasAuthorship W2514912829A5060122908 @default.
• W2514912829 hasAuthorship W2514912829A5069157708 @default.
• W2514912829 hasBestOaLocation W25149128291 @default.
• W2514912829 hasConcept C126322002 @default.
• W2514912829 hasConcept C126894567 @default.
• W2514912829 hasConcept C141071460 @default.
• W2514912829 hasConcept C142724271 @default.
• W2514912829 hasConcept C168563851 @default.
• W2514912829 hasConcept C203092338 @default.
• W2514912829 hasConcept C204787440 @default.
• W2514912829 hasConcept C27081682 @default.
• W2514912829 hasConcept C2777385986 @default.
• W2514912829 hasConcept C2779721657 @default.
• W2514912829 hasConcept C2779881121 @default.
• W2514912829 hasConcept C2780261098 @default.
• W2514912829 hasConcept C2780402116 @default.
• W2514912829 hasConcept C71924100 @default.
• W2514912829 hasConcept C90924648 @default.
• W2514912829 hasConceptScore W2514912829C126322002 @default.
• W2514912829 hasConceptScore W2514912829C126894567 @default.
• W2514912829 hasConceptScore W2514912829C141071460 @default.
• W2514912829 hasConceptScore W2514912829C142724271 @default.
• W2514912829 hasConceptScore W2514912829C168563851 @default.
• W2514912829 hasConceptScore W2514912829C203092338 @default.
• W2514912829 hasConceptScore W2514912829C204787440 @default.
• W2514912829 hasConceptScore W2514912829C27081682 @default.
• W2514912829 hasConceptScore W2514912829C2777385986 @default.
• W2514912829 hasConceptScore W2514912829C2779721657 @default.
• W2514912829 hasConceptScore W2514912829C2779881121 @default.
• W2514912829 hasConceptScore W2514912829C2780261098 @default.
• W2514912829 hasConceptScore W2514912829C2780402116 @default.
• W2514912829 hasConceptScore W2514912829C71924100 @default.
• W2514912829 hasConceptScore W2514912829C90924648 @default.
• W2514912829 hasIssue "1" @default.
• W2514912829 hasLocation W25149128291 @default.

• next